NasdaqCM - Nasdaq Real Time Price USD

Cingulate Inc. (CING)

4.3500

+0.1000

+(2.35%)

As of 3:53:53 PM EDT. Market Open.

Cingulate secures $3m to advance once-daily anxiety treatment

The grant will be distributed in three $1m tranches, with the first payment scheduled for 1 May 2025.

Pharmaceutical Technology 14 days ago

CINGW
CING: 2024 Financial and Operational Results

By John Vandermosten, CFA NASDAQ:CING READ THE FULL CING RESEARCH REPORT Cingulate, Inc. (NASDAQ:CING) reported 2024 results on March 26 th , 2025. No revenues were recorded and operating expense of $15.6 million was recognized. Over the last several months, Cingulate has raised meaningful capital, completed its fast-fed study and reported safety results from its Phase III trials. As we review

Zacks Small Cap Research 14 days ago

CINGW
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Market Worldwide Non-Dilutive Funding Expands Pipeline and Further Validates Cingulate’s Proprietary Precision Timed Release™ Drug Delivery Technology CTx-2103 has the Potential to Reduce Use of Benzodiazepine’s and Associated Withdrawal and Dependency Issues KANSAS CITY, Kan., April 09, 2025 (GLOBE NEWSWI

GlobeNewswire 15 days ago

CING
+2.35%
CINGW
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301

NDA Submission On-Target for Mid-2025KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced that it held a Pre-NDA meeting with the U.S. Food and Drug Administration (FDA) yesterday to discuss the submission of a new drug application (NDA) for its lead Phase 3 ass

GlobeNewswire 21 days ago

CING
+2.35%
CINGW
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025$17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for NDA Submission KANSAS CITY, Kan., March 26, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, toda

GlobeNewswire 28 days ago

CING
+2.35%
CINGW
CING: April Pre-NDA Meeting

By John Vandermosten, CFA NASDAQ:CING READ THE FULL CING RESEARCH REPORT Since the report of third quarter results, Cingulate, Inc. (NASDAQ:CING) has executed a $5 million capital raise, completed its fast-fed study and reported safety results from its Phase III trials. As we move down the home stretch towards the FDA submission, Cingulate has a pre-new drug application (NDA) meeting scheduled

Zacks Small Cap Research last month

CINGW
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025

Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2 CTx-1301 is the First, True, Once-Daily Stimulant Medication to Treat ADHD Over the Entire Active Day KANSAS CITY, Kan., March 04, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today released Phase 3 safety data fo

GlobeNewswire last month

CING
+2.35%
CINGW
Final Study Completed for Cingulate’s Lead Asset CTx-1301

No Serious Adverse Events ReportedSubmission of New Drug Application Targeted for Mid 2025 KANSAS CITY, Kan., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has completed its final FDA-required study, which is a food effect study, for CTx-1301 (dexmethylphenidat

GlobeNewswire 3 months ago

CING
+2.35%
CINGW
Cingulate Inc Secures $5M Financing for Strategic Growth

The latest announcement is out from Cingulate Inc ( (CING) ). Cingulate Inc. has secured a $5 million financing arrangement through an unsecured promissory note with Streeterville Capital, LLC. The funds will support clinical, manufacturing, and regulatory activities, extending the company’s cash runway into the fourth quarter of 2025. This financial move strategically positions Cingulate to advance its drug pipeline, including the anticipated mid-2025 NDA filing for CTx-1301, potentially enhanc

TipRanks 3 months ago

CING
+2.35%
CINGW
Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Cash Runway Extended Beyond Planned NDA Submission of CTx-1301KANSAS CITY, Kan., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, has completed a financing transaction with an accredited investor which provided net proceeds to CING of $5 million. The transaction was structured as a non-c

GlobeNewswire 3 months ago

CING
+2.35%
CINGW
CING: Third Quarter Results

By John Vandermosten, CFA NYSE:CING READ THE FULL CING RESEARCH REPORT Cingulate, Inc. (NASDAQ:CING) reported third quarter results on November 7 th , 2024. No revenues were reported and operating expense of $3.3 million was recognized. During the third quarter and to date the company was issued a European patent for tripulse stimulant formulations, participated in multiple business media

Zacks Small Cap Research 5 months ago

CINGW
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

On Target for Mid-2025 New Drug Application (NDA) Submission of lead ADHD asset CTx-1301KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended September 30, 2024, and provided a clinical and business update. “T

GlobeNewswire 5 months ago

CING
+2.35%
CINGW
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, recently joined the cast of the Big Biz Show, a business and finance broadcast, to discuss Cingulate’s lead Phase 3 asset CTx-1301 for the treatment of ADHD, its plans for commercia

GlobeNewswire 6 months ago

CING
+2.35%
CINGW
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

$10 Million of additional Capital Recently Raised Strengthening Balance SheetKANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has commenced its final FDA-required study, which is a food effect study, for CTx-1301 (dexmethylphenidate) for the tr

GlobeNewswire 7 months ago

CING
+2.35%
CINGW
Cingulate to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on August 28, 2024, at 10:30 a.m. CST. Along with a company overview, Dr. Schaffer will discuss Cingul

GlobeNewswire 7 months ago

CING
+2.35%
CINGW
CING: Initiating Coverage – Precision Timed Release Delivers Active-Day Coverage

By John Vandermosten, CFA NYSE:CING READ THE FULL CING RESEARCH REPORT We are initiating coverage of Cingulate, Inc. (NYSE:CING) with a target price of $70.00 per share. This value is based on our forecasts for the successful development and commercialization of CTx-1301 for Attention Deficit/ Hyperactivity Disorder (ADHD). Cingulate’s candidate uses its licensed precision timed release (PTR)

Zacks Small Cap Research 7 months ago

CINGW
Cingulate Announces Adjournment of Special Meeting

KANSAS CITY, Kan., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), (“Cingulate” or the “Company”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has adjourned its Special Meeting of Stockholders (the “Special Meeting”) in order to provide stockholders additional time within which to vote on all proposals. At

GlobeNewswire 7 months ago

CING
+2.35%
CINGW
Top Midday Decliners

Top Midday Decliners

PREMIUM
MT Newswires 8 months ago

CINGW

LQDA
Top Midday Gainers

Top Midday Gainers

PREMIUM
MT Newswires 8 months ago

CINGW
Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

KANSAS CITY, Kan., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it was issued a European patent for its lead asset CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The patent application was granted on August 14,

GlobeNewswire 8 months ago

CING
+2.35%
CINGW

Performance Overview

Return	CING	S&P 500 (^GSPC)
YTD	-11.76%	-6.68%
1-Year	-58.33%	+8.23%
3-Year	-98.91%	+28.49%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cingulate Inc. (CING)

Cingulate secures $3m to advance once-daily anxiety treatment

CING: 2024 Financial and Operational Results

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

CING: April Pre-NDA Meeting

Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025

Final Study Completed for Cingulate’s Lead Asset CTx-1301

Cingulate Inc Secures $5M Financing for Strategic Growth

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

CING: Third Quarter Results

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Cingulate to Participate in Benzinga All Live Access Event

CING: Initiating Coverage – Precision Timed Release Delivers Active-Day Coverage

Cingulate Announces Adjournment of Special Meeting

Top Midday Decliners

Top Midday Gainers

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Performance Overview